Fig. 3From: Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trialChanges from baseline in the late potentials. Intragroup and intergroup comparison revealed no significant change in late potentials as an indicator of depolarizationBack to article page